A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy
Latest Information Update: 31 Mar 2022
At a glance
- Drugs Alemtuzumab (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms CARE-MS-II
- Sponsors Genzyme Corporation
- 22 Apr 2021 Results of pooled data of CARE-MS studies (NCT00530348; NCT00548405; NCT00930553) presented at the 73rd Annual Meeting of the American Academy of Neurology.
- 13 Sep 2020 Results (n=1216) of analysis assessing autoimmune adverse events from five clinical studies: NCT00050778, NCT00530348, NCT00548405, NCT00930553, NCT02255656 presented at the 8th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
- 26 May 2020 Results presenting incidences of acute adverse events (AEs) reported during infusion and in the days following in the CARE-MS studies and postmarketing setting presented at the 6th Congress of the European Academy of Neurology